Gabrielle Agin-Liebes
Clinical Researcher in Psychedelic Psychotherapy
Data updated
Research Footprint
Gabrielle Agin-Liebes appears in 15 tracked papers (2016–2025), most studied alongside Psilocybin, Mescaline and Ayahuasca, across Depressive Disorders, Anxiety Disorders and Palliative & End-of-Life Distress.
Most-cited paper: Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial (1678 citations).
Frequent co-authors: James Guss, Alison Bossis and Stephen Ross.
Publication Landscape
How the 15 papers Blossom tracks for Gabrielle Agin-Liebes line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Gabrielle Agin-Liebes's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 15 of 15 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Gabrielle Agin-Liebes publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Gabrielle Agin-Liebes publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Gabrielle Agin-Liebes is a clinical researcher specialising in psychedelic-assisted therapies, with a primary focus on psilocybin clinical trials and follow-up research in populations with life-threatening cancer and comorbid psychiatric distress. She has been a co‑author on multiple influential studies reporting acute and sustained reductions in anxiety, depression, loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy, and contributed to long‑term follow‑up work that characterises durability of therapeutic effects. Her work sits at the intersection of clinical trial conduct, outcome assessment for existential and psychiatric suffering, and translation of psychedelic protocols into clinical practice.
In addition to trial-oriented publications, Agin-Liebes has contributed to the broader evidence base through survey and methodological work (including studies of clinicians' attitudes toward psychedelic therapies), citizen‑science investigations of microdosing, and preliminary community‑based research on other plant‑medicine models (e.g., ayahuasca). Her research portfolio indicates sustained engagement with both empirical clinical outcomes and the contextual, ethical and implementation questions necessary for integrating psychedelic therapies into mainstream psychiatric and substance‑use treatment pathways.
Key Impact
Notable for her contributions to clinical research on psilocybin-assisted psychotherapy, particularly long-term follow-up studies of cancer-related psychiatric and existential distress and related work on suicidality and substance-use applications.
Collaboration Network
27 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Gabrielle Agin-Liebes's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Gabrielle Agin-Liebes is associated with.
Yale School of Medicine Center for Brain Mind Health
academicThe Center for Brain and Mind Health at Yale School of Medicine bridges psychiatry and neuroscience, and is the institutional home of the Yale Program for Psychedelic Science. Both are directed by Christopher Pittenger, with Benjamin Kelmendi a central figure in the psychedelic studies. Yale's involvement is long-standing: serotonin's role in the action of LSD was first described here by George Aghajanian in the 1960s. Current work focuses on the psychological, neurobiological and therapeutic effects of psychedelics, with a notable strand examining psilocybin for obsessive-compulsive disorder, drawing on the group's clinical experience in Yale's OCD research clinic. The programme supports a broad, multidisciplinary community of investigators rather than a single treatment line.
View stakeholder →VA Connecticut Healthcare System
governmentThe VA Connecticut Healthcare System provides comprehensive medical and mental health services to veterans across Connecticut, with campuses in West Haven and Newington. As part of the VA's expanding psychedelic research program, it participates in clinical trials investigating MDMA-assisted therapy and psilocybin for PTSD and related conditions affecting veterans.
View stakeholder →NYU Grossman School of Medicine
NYU Grossman School of Medicine is New York University's medical school and a core academic unit of NYU Langone Health. It provides MD and other medical education, conducts biomedical research, and delivers clinical care in the United States.
View stakeholder →